Cervical cancer has the highest incidence among the three major gynecological malignancies and ranks fourth in both incidence and mortality among female malignancies, with its incidence continuing to rise. Early-stage cervical cancer is primarily treated with surgery, while concurrent chemoradiotherapy is the main treatment for advanced stages. For recurrent or metastatic cervical cancer, systemic treatment is the primary approach. The survival rate of patients with recurrent or metastatic cervical cancer is low, prognosis is poor, and treatment options are limited. The pharmacological treatment of recurrent or metastatic cervical cancer has evolved through several stages, including cisplatin monotherapy, platinum-based doublet chemotherapy, targeted therapy represented by bevacizumab, immunotherapy, and antibody-drug conjugates. While a relatively systematic treatment guideline has been established, recent advancements in drug development, the continuous updating of clinical trial results, and the exploration of combination therapies with different mechanisms of action underscore the need for an updated summary of the progress in pharmacological treatments for recurrent or metastatic cervical cancer to help clinicians expand therapeutic options for patients.

宫颈癌发病率居妇科三大恶性肿瘤之首，发病率与死亡率居女性恶性肿瘤第4位，且仍呈上升趋势。宫颈癌早期以手术治疗为主，中晚期以同步放化疗为主，复发或转移以系统治疗为主。复发或转移性宫颈癌患者的生存率低，预后差，治疗选择有限。复发或转移性宫颈癌的药物治疗经历了顺铂单药治疗、含铂双联化疗及以贝伐珠单抗为代表的靶向治疗、免疫治疗和抗体偶联药物治疗等发展阶段，虽已形成较为系统的治疗选择标准，但随着近年来治疗药物的不断迭代开发，药物临床试验成果的不断更新，不同作用机制的药物联合治疗模式也在不断探索中。因此，有必要对复发或转移性宫颈癌的药物治疗进展进行总结，供临床医师掌握，为患者提供更多治疗选择。